{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T22:45:36Z","timestamp":1783723536385,"version":"3.55.0"},"reference-count":39,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2023,1,5]],"date-time":"2023-01-05T00:00:00Z","timestamp":1672876800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Grant-in-Aid for Scientific Research (B)","award":["20H03568"],"award-info":[{"award-number":["20H03568"]}]},{"name":"Grant-in-Aid for Scientific Research (B)","award":["22H02956"],"award-info":[{"award-number":["22H02956"]}]},{"name":"Grant-in-Aid for Scientific Research (B)","award":["19K17817"],"award-info":[{"award-number":["19K17817"]}]},{"name":"Grant-in-Aid for Scientific Research (B)","award":["21K16307"],"award-info":[{"award-number":["21K16307"]}]},{"name":"Grant-in-Aid for Early-Career Scientists","award":["20H03568"],"award-info":[{"award-number":["20H03568"]}]},{"name":"Grant-in-Aid for Early-Career Scientists","award":["22H02956"],"award-info":[{"award-number":["22H02956"]}]},{"name":"Grant-in-Aid for Early-Career Scientists","award":["19K17817"],"award-info":[{"award-number":["19K17817"]}]},{"name":"Grant-in-Aid for Early-Career Scientists","award":["21K16307"],"award-info":[{"award-number":["21K16307"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cells"],"abstract":"<jats:p>Dupilumab attenuates itch and skin inflammation in patients with atopic dermatitis (AD). However, itch-related events that are improved by dupilumab remain unclear. Therefore, the present study investigated changes in clinical scores, serum biomarkers, and the number of intraepidermal nerve fibers (IENFs) using skin biopsies and blood samples from 12 patients with moderate to severe AD before and after treatment with dupilumab. Clinical manifestations were assessed using eczema area and severity index (EASI) and visual analogue scale (VAS) scores at baseline and after 8 and 16 weeks of treatment. Serum levels of total immunoglobulin E (IgE), thymus and activation-regulated chemokine (TARC), interleukin (IL)-4, IL-13, IL-22, and IL-31 were examined by electrochemiluminescence, chemiluminescent enzyme immunoassays, ProQuantum immunoassays, and enzyme-linked immunosorbent assays (ELISA) at baseline and after 8 and 16 weeks of treatment. In skin biopsies from AD patients at baseline and after 16 weeks of treatment, IENFs were examined immunohistochemically with the anti-protein gene product (PGP) 9.5 antibody. The dupilumab treatment significantly improved EASI and VAS scores and decreased serum levels of TARC, IgE, and IL-22, whereas those of IL-13 and IL-31, and the number of IENFs remained unchanged and those of IL-4 increased. VAS scores were positively correlated with serum TARC, IL-22, and IgE levels and the degree of epidermal thickening. Serum IL-31 levels were positively correlated with the number of IENFs. These results suggest that serum TARC, IL-22, and IgE levels and epidermal thickness are itch-related events associated with dupilumab treatment and that serum IL-31 levels may reflect the degree of IENF density in AD patients. Therefore, dynamic changes may be used to assess the efficacy of dupilumab treatment to treat itching and inflammation in patients with AD.<\/jats:p>","DOI":"10.3390\/cells12020239","type":"journal-article","created":{"date-parts":[[2023,1,6]],"date-time":"2023-01-06T02:20:30Z","timestamp":1672971630000},"page":"239","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Effects of Dupilumab on Itch-Related Events in Atopic Dermatitis: Implications for Assessing Treatment Efficacy in Clinical Practice"],"prefix":"10.3390","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3999-1609","authenticated-orcid":false,"given":"Ryoma","family":"Kishi","sequence":"first","affiliation":[{"name":"Juntendo Itch Research Center (JIRC), Institute for Environmental and Gender-Specific Medicine, Juntendo University Graduate School of Medicine, 2-1-1 Tomioka, Urayasu 279-0021, Chiba, Japan"},{"name":"Department of Dermatology, Juntendo University Urayasu Hospital, 2-1-1 Tomioka, Urayasu 279-0021, Chiba, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3606-245X","authenticated-orcid":false,"given":"Sumika","family":"Toyama","sequence":"additional","affiliation":[{"name":"Juntendo Itch Research Center (JIRC), Institute for Environmental and Gender-Specific Medicine, Juntendo University Graduate School of Medicine, 2-1-1 Tomioka, Urayasu 279-0021, Chiba, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1254-1803","authenticated-orcid":false,"given":"Mitsutoshi","family":"Tominaga","sequence":"additional","affiliation":[{"name":"Juntendo Itch Research Center (JIRC), Institute for Environmental and Gender-Specific Medicine, Juntendo University Graduate School of Medicine, 2-1-1 Tomioka, Urayasu 279-0021, Chiba, Japan"},{"name":"Anti-Aging Skin Research Laboratory, Juntendo University Graduate School of Medicine, 2-1-1 Tomioka, Urayasu 279-0021, Chiba, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3477-5715","authenticated-orcid":false,"given":"Yayoi","family":"Kamata","sequence":"additional","affiliation":[{"name":"Juntendo Itch Research Center (JIRC), Institute for Environmental and Gender-Specific Medicine, Juntendo University Graduate School of Medicine, 2-1-1 Tomioka, Urayasu 279-0021, Chiba, Japan"},{"name":"Anti-Aging Skin Research Laboratory, Juntendo University Graduate School of Medicine, 2-1-1 Tomioka, Urayasu 279-0021, Chiba, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eriko","family":"Komiya","sequence":"additional","affiliation":[{"name":"Juntendo Itch Research Center (JIRC), Institute for Environmental and Gender-Specific Medicine, Juntendo University Graduate School of Medicine, 2-1-1 Tomioka, Urayasu 279-0021, Chiba, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahide","family":"Kaneko","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Juntendo University Urayasu Hospital, 2-1-1 Tomioka, Urayasu 279-0021, Chiba, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3643-2879","authenticated-orcid":false,"given":"Yasushi","family":"Suga","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Juntendo University Urayasu Hospital, 2-1-1 Tomioka, Urayasu 279-0021, Chiba, Japan"},{"name":"Anti-Aging Skin Research Laboratory, Juntendo University Graduate School of Medicine, 2-1-1 Tomioka, Urayasu 279-0021, Chiba, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0644-0504","authenticated-orcid":false,"given":"Kenji","family":"Takamori","sequence":"additional","affiliation":[{"name":"Juntendo Itch Research Center (JIRC), Institute for Environmental and Gender-Specific Medicine, Juntendo University Graduate School of Medicine, 2-1-1 Tomioka, Urayasu 279-0021, Chiba, Japan"},{"name":"Department of Dermatology, Juntendo University Urayasu Hospital, 2-1-1 Tomioka, Urayasu 279-0021, Chiba, Japan"},{"name":"Anti-Aging Skin Research Laboratory, Juntendo University Graduate School of Medicine, 2-1-1 Tomioka, Urayasu 279-0021, Chiba, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,1,5]]},"reference":[{"key":"ref_1","first-page":"e315","article-title":"English Version of Clinical Practice Guidelines for the Management of Atopic Dermatitis 2021","volume":"49","author":"Saeki","year":"2022","journal-title":"J. Dermatol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1111\/all.13401","article-title":"Epidemiology of atopic dermatitis in adults: Results from an international survey","volume":"73","author":"Barbarot","year":"2018","journal-title":"Allergy"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.jaad.2015.10.043","article-title":"Patient burden of moderate to severe atopic dermatitis (AD): Insights from a phase 2b clinical trial of dupilumab in adults","volume":"74","author":"Simpson","year":"2016","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.jid.2016.07.012","article-title":"The burden of atopic dermatitis: Summary of a report for the National Eczema Association","volume":"137","author":"Drucker","year":"2017","journal-title":"J. Invest. Dermatol."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Moniaga, C.S., Tominaga, M., and Takamori, K. (2021). The Pathology of Type 2 Inflammation-Associated Itch in Atopic Dermatitis. Diagnostics, 11.","DOI":"10.3390\/diagnostics11112090"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.jaci.2013.07.049","article-title":"Efficacy and safety of systemic treatments for moderate-to-severe atopic dermatitis: A systemic review","volume":"133","author":"Roekevisch","year":"2014","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1177\/1203475416670364","article-title":"Review of systemic treatment options for adult atopic dermatitis","volume":"21","author":"Gooderham","year":"2017","journal-title":"J. Cutan. Med. Surg."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Toyama, S., Tominaga, M., and Takamori, K. (2022). Treatment options for troublesome itch. Pharmaceuticals, 15.","DOI":"10.3390\/ph15081022"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1111\/all.14151","article-title":"Dual blockade of IL-4 and IL-13 with dupilumab, an IL-4R\u03b1 antibody, is required to broadly inhibit type 2 inflammation","volume":"75","author":"Allinne","year":"2020","journal-title":"Allergy"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa1610020","article-title":"Two phase 3 trials of dupilumab versus placebo in atopic dermatitis","volume":"375","author":"Simpson","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1016\/S0140-6736(17)31191-1","article-title":"Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): A 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial","volume":"389","author":"Blauvelt","year":"2017","journal-title":"Lancet"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1067\/mai.2001.113237","article-title":"Thymus and activation-regulated chemokine in atopic dermatitis: Serum thymus and activation-regulated chemokine level is closely related with disease activity","volume":"107","author":"Kakinuma","year":"2001","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"673","DOI":"10.4103\/0019-5154.91827","article-title":"Study of the role of serum folic acid in atopic dermatitis: A correlation with serum IgE and disease severity","volume":"56","author":"Shaheen","year":"2011","journal-title":"Indian J. Dermatol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"246","DOI":"10.4103\/0378-6323.16615","article-title":"Correlation of the severity of atopic dermatitis with absolute eosinophil counts in peripheral blood and serum IgE levels","volume":"71","author":"Dhar","year":"2005","journal-title":"Indian J. Dermatol. Venereol. Leprol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1111\/ijd.15183","article-title":"Dupilumab treatment ameliorates clinical and hematological symptoms, including blood eosinophilia, in patients with atopic dermatitis","volume":"60","author":"Yamauchi","year":"2021","journal-title":"Int. J. Dermatol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1111\/all.14080","article-title":"Dupilumab is very effective in a large cohort of difficult-to-treat adult atopic dermatitis patients: First clinical and biomarker results from the BioDay registry","volume":"75","author":"Schaft","year":"2020","journal-title":"Allergy"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.alit.2022.04.003","article-title":"Peripheral itch sensitization in atopic dermatitis","volume":"71","author":"Tominaga","year":"2022","journal-title":"Allergol. Int."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1111\/1346-8138.12317","article-title":"Itch and nerve fibers with special reference to atopic dermatitis: Therapeutic implications","volume":"41","author":"Tominaga","year":"2014","journal-title":"J. Dermatol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.cell.2017.08.006","article-title":"Sensory neurons co-opt classical immune signaling pathways to mediate chronic itch","volume":"171","author":"Oetjen","year":"2017","journal-title":"Cell"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Toyama, S., Tominaga, M., and Takamori, K. (2021). Connections between immune-derived mediators and sensory nerves for itch sensation. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms222212365"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"44","DOI":"10.2340\/00015555924447","article-title":"Diagnostic features of atopic dermatitis","volume":"92","author":"Hanifin","year":"1980","journal-title":"Acta Derm Venereol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1111\/bjd.13662","article-title":"What the eczema area and severity index score tells us about the severity of atopic dermatitis: An interpretability study","volume":"172","author":"Leshem","year":"2015","journal-title":"Br. J. Dermatol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"502","DOI":"10.2340\/00015555-1246","article-title":"Assessment of pruritus intensity: Prospective study on validity and reliability of the visual analogue scale, numerical rating scale and verbal rating scale in 471 patients with chronic pruritus","volume":"92","author":"Phan","year":"2012","journal-title":"Acta Derm. Venereol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.jaad.2019.02.053","article-title":"Effectiveness and safety of dupilumab for the treatment of atopic dermatitis in a real-life French multicenter adult cohort","volume":"81","author":"Faiz","year":"2019","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1056\/NEJMoa1804092","article-title":"Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma","volume":"378","author":"Castro","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"170ra16","DOI":"10.1126\/scitranslmed.3005374","article-title":"TSLP elicits IL-33-independent innate lymphoid cell responses to promote skin inflammation","volume":"5","author":"Kim","year":"2013","journal-title":"Sci. Transl. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"13291","DOI":"10.1073\/pnas.1307321110","article-title":"Skin-specific expression of IL-33 activates group 2 innate lymphoid cells and elicits atopic dermatitis-like inflammation in mice","volume":"110","author":"Imai","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1001\/jamadermatol.2019.3617","article-title":"Efficacy and safety of multiple dupilumab dose regimens after initial successful treatment in patients with atopic dermatitis: A randomized clinical trial","volume":"156","author":"Worm","year":"2020","journal-title":"JAMA Dermatol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.ejphar.2016.11.020","article-title":"Demonstration of rebound phenomenon following abrupt withdrawal of the JAK1 inhibitor oclacitinib","volume":"794","author":"Fukuyama","year":"2017","journal-title":"Eur. J. Pharmacol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1152\/physrev.00017.2019","article-title":"Physiology and pathophysiology of itch","volume":"100","author":"Cevikbas","year":"2020","journal-title":"Physiol. Rev."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"e3037","DOI":"10.1126\/scitranslmed.abe3037","article-title":"OncostatinM can sensitize sensory neurons in inflammatory pruritus","volume":"13","author":"Tseng","year":"2021","journal-title":"Sci. Transl. Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.jaci.2016.02.020","article-title":"The pruritus- and TH2-associated cytokine IL-31 promotes growth of sensory nerves","volume":"138","author":"Feld","year":"2016","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Furue, M. (2020). Regulation of filaggrin, loricrin, and involucrin by IL-4, IL-13, IL-17 A, IL-22, AHR, and NRF 2: Pathogenic implications in atopic dermatitis. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21155382"},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Takemura, M., Nakahara, T., Hashimoto-Hachiya, A., Furue, M., and Tsuji, G. (2018). Glyteer, soybean tar, impairs IL-4\/Stat6 signaling in murine bone marrow-derived dendritic cells: The basis of its therapeutic effect on atopic dermatitis. Int. J. Mol. Sci., 19.","DOI":"10.3390\/ijms19041169"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/j.coi.2010.10.013","article-title":"IL-17 and IL-22 in atopic allergic disease","volume":"22","author":"Souwer","year":"2010","journal-title":"Curr. Opin. Immunol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"3695","DOI":"10.4049\/jimmunol.174.6.3695","article-title":"IL-22 inhibits epidermal differentiation and induces proinflammatory gene expression and migration of human keratinocytes","volume":"174","author":"Boniface","year":"2005","journal-title":"J. Immunol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.jaci.2018.08.022","article-title":"Dupilumab progressively improves systemic and cutaneous abnormalities in patients with atopic dermatitis","volume":"143","author":"Bissonnette","year":"2019","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1038\/ni.1767","article-title":"Production of interleukin 22 but not interleukin 17 by a subset of human skin-homing memory T cells","volume":"10","author":"Duhen","year":"2009","journal-title":"Nat. Immunol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.jdermsci.2010.08.013","article-title":"Significant correlation of serum IL-22 levels with CCL17 levels in atopic dermatitis","volume":"61","author":"Hayashida","year":"2011","journal-title":"J. Dermatol. Sci."}],"container-title":["Cells"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4409\/12\/2\/239\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T18:00:37Z","timestamp":1760119237000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4409\/12\/2\/239"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,5]]},"references-count":39,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2023,1]]}},"alternative-id":["cells12020239"],"URL":"https:\/\/doi.org\/10.3390\/cells12020239","relation":{},"ISSN":["2073-4409"],"issn-type":[{"value":"2073-4409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,5]]}}}